Literature DB >> 8636649

Accumulation of bisphosphonates in the aorta and some other tissues of healthy and atherosclerotic rabbits.

R Ylitalo1, J Mönkkönen, A Urtti, P Ylitalo.   

Abstract

Clodronate, etidronate, and pamidronate are highly hydrophilic bisphosphonates used for the treatment of bone resorption and hypercalcemia. They also inhibit the development of experimental atherosclerosis without influencing serum cholesterol level. We studied the distribution and the accumulation of the carbon 14-labeled bisphosphonates in the aorta and some other tissues of healthy rabbits and in rabbits with diet-induced atherosclerosis. After intravenous injection, clodronate and pamidronate disappeared from circulation more slowly in atherosclerotic than in healthy rabbits, and the drug concentrations in the peripheral tissues were generally lower in atherosclerotic than in healthy animals. At 24 hours after dosing in healthy rabbits, the mean aorta to plasma ratios of clodronate, etidronate, and pamidronate were, respectively, 2.4 to 2.8, 2.4 to 4.0, and 8.6 to 10. The corresponding ratios in atherosclerotic rabbits were, respectively, 13 to 22, 1.5 to 2.2, and 13 to 24. Seven days after the injection the mean clodronate concentration in the aortas of healthy rabbits was 0.5% to 0.9% of the dose given per tissue weight, and the concentration in those of atherosclerotic animals was 3.8% to 5.2% of the dose given per tissue weight. The results indicate that hydrophilic bisphosphonates, known to inhibit the atherogenesis, concentrate markedly in the aortas of healthy and atherosclerotic rabbits.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8636649     DOI: 10.1016/s0022-2143(96)90079-7

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  12 in total

1.  A population-based 2-year follow-up study on the relationship between bisphosphonates and the risk of stroke.

Authors:  J-H Kang; J J Keller; H-C Lin
Journal:  Osteoporos Int       Date:  2012-01-20       Impact factor: 4.507

2.  Vacuolar proton pyrophosphatase activity and pyrophosphate (PPi) in Toxoplasma gondii as possible chemotherapeutic targets.

Authors:  C O Rodrigues; D A Scott; B N Bailey; W De Souza; M Benchimol; B Moreno; J A Urbina; E Oldfield; S N Moreno
Journal:  Biochem J       Date:  2000-08-01       Impact factor: 3.857

3.  Differential effect of zoledronic acid on human vascular smooth muscle cells.

Authors:  Hassan Albadawi; Mounir J Haurani; Rahmi Oklu; Jordan P Trubiano; Peter J Laub; Hyung-Jin Yoo; Michael T Watkins
Journal:  J Surg Res       Date:  2012-11-08       Impact factor: 2.192

4.  Therapeutic perspectives.

Authors:  Carmelo E Fiore; Pietra Pennisi; Marianna Tinè
Journal:  Clin Cases Miner Bone Metab       Date:  2008-01

5.  Use of bisphosphonate and risk of atrial fibrillation in older women with osteoporosis.

Authors:  C W Rhee; J Lee; S Oh; N K Choi; B J Park
Journal:  Osteoporos Int       Date:  2011-03-24       Impact factor: 4.507

6.  Effect of etidronic acid on arterial calcification in dialysis patients.

Authors:  Tsuneo Ariyoshi; Kiyoyuki Eishi; Ichiro Sakamoto; Seiji Matsukuma; Tomohiro Odate
Journal:  Clin Drug Investig       Date:  2006       Impact factor: 2.859

7.  Bisphosphonates and mortality in women with CKD and the presence or absence of cardiovascular disease.

Authors:  Robert M Perkins; H Lester Kirchner; Kunihiro Matsushita; Ion D Bucaloiu; Evan Norfolk; James E Hartle
Journal:  Clin J Am Soc Nephrol       Date:  2014-02-27       Impact factor: 8.237

8.  Bisphosphonate use is associated with reduced risk of myocardial infarction in patients with rheumatoid arthritis.

Authors:  Frederick Wolfe; Marcy B Bolster; Christopher M O'Connor; Kaleb Michaud; Kenneth W Lyles; Cathleen S Colón-Emeric
Journal:  J Bone Miner Res       Date:  2013-05       Impact factor: 6.741

9.  Alendronate and risk of lower limb ischemic vascular events: a population-based cohort study.

Authors:  C-K Chen; H-T Chang; H-P Chou; M-H Lee; Y-C Chen; Y-C Huang; T-J Chen; H-L Chang; C-C Shih
Journal:  Osteoporos Int       Date:  2013-08-14       Impact factor: 4.507

10.  Vascular effects of bisphosphonates-a systematic review.

Authors:  Leyna L Santos; Taciana B Cavalcanti; Francisco A Bandeira
Journal:  Clin Med Insights Endocrinol Diabetes       Date:  2012-10-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.